2019年欧洲心脏病学会/欧洲动脉粥样硬化学会(European Society of Cardiology/European Atherosclerosis Society,ESC/EAS)血脂管理指南(以下简称2019欧洲血脂指南)的问世被列为2019年心血管领域重要事件之一绝不过分,其首要的理由是...2019年欧洲心脏病学会/欧洲动脉粥样硬化学会(European Society of Cardiology/European Atherosclerosis Society,ESC/EAS)血脂管理指南(以下简称2019欧洲血脂指南)的问世被列为2019年心血管领域重要事件之一绝不过分,其首要的理由是动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)的全球发病态势明显增加,而血脂领域研究的突出进展与成就也功含其中。事实上,胆固醇尤其是低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C),作为ASCVD发生的病因性危险因素可以说是人人皆知[1-5],但其与ASCVD的关系仍旧令人困惑。LDL-C到底多低为好?为什么积极降LDL-C治疗存在残余心血管风险(residual cardiovascular risk,RCVR)?新型调脂药物如前蛋白转化酶枯草杆菌蛋白酶/kexin9型(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂如何应用?这些问题常常影响着临床血脂防治工作的质量。2019欧洲血脂指南的及时问世,为现今我国的血脂管理提供了新的方向,笔者就2019欧洲血脂指南的要点作一概述。展开更多
Nattokinase is a novel fibrinolytic en- zyme, which is homologous to Subtilisin Carlsberg. In this paper, Subtilisin Carlsberg was taken as a model protein of nattokinase. Effects of pH, ionic strength, concentration ...Nattokinase is a novel fibrinolytic en- zyme, which is homologous to Subtilisin Carlsberg. In this paper, Subtilisin Carlsberg was taken as a model protein of nattokinase. Effects of pH, ionic strength, concentration of isopropanol on the extraction of Subtilisin Carlsberg with AOT/isooctane reverse mi- celles system were investigated. Further, the process of reverse micelles extraction of nattokinase from fermentation broth was studied. By taking the reverse micelles of AOT/isooctane as extractant to perform a full extraction cycle, it was found that about eighty percent of the total activity of nattokinase in the fer- mentation broth could be recovered and the purifica- tion factor was about 2.5. Homologous protein could be reasonably used as model protein of a target protein.展开更多
文摘2019年欧洲心脏病学会/欧洲动脉粥样硬化学会(European Society of Cardiology/European Atherosclerosis Society,ESC/EAS)血脂管理指南(以下简称2019欧洲血脂指南)的问世被列为2019年心血管领域重要事件之一绝不过分,其首要的理由是动脉粥样硬化性心血管疾病(atherosclerotic cardiovascular disease,ASCVD)的全球发病态势明显增加,而血脂领域研究的突出进展与成就也功含其中。事实上,胆固醇尤其是低密度脂蛋白胆固醇(low density lipoprotein cholesterol,LDL-C),作为ASCVD发生的病因性危险因素可以说是人人皆知[1-5],但其与ASCVD的关系仍旧令人困惑。LDL-C到底多低为好?为什么积极降LDL-C治疗存在残余心血管风险(residual cardiovascular risk,RCVR)?新型调脂药物如前蛋白转化酶枯草杆菌蛋白酶/kexin9型(proprotein convertase subtilisin/kexin type 9,PCSK9)抑制剂如何应用?这些问题常常影响着临床血脂防治工作的质量。2019欧洲血脂指南的及时问世,为现今我国的血脂管理提供了新的方向,笔者就2019欧洲血脂指南的要点作一概述。
基金supported by the Creative Research Group of the National Natural Science Foundation of China(Grant No.20221603).
文摘Nattokinase is a novel fibrinolytic en- zyme, which is homologous to Subtilisin Carlsberg. In this paper, Subtilisin Carlsberg was taken as a model protein of nattokinase. Effects of pH, ionic strength, concentration of isopropanol on the extraction of Subtilisin Carlsberg with AOT/isooctane reverse mi- celles system were investigated. Further, the process of reverse micelles extraction of nattokinase from fermentation broth was studied. By taking the reverse micelles of AOT/isooctane as extractant to perform a full extraction cycle, it was found that about eighty percent of the total activity of nattokinase in the fer- mentation broth could be recovered and the purifica- tion factor was about 2.5. Homologous protein could be reasonably used as model protein of a target protein.
